Schizophrenia: a Multisystem Disease?

Overview

Journal J Psychopharmacol

Publisher Sage Publications

Specialty Pharmacology

Date 2010 Oct 7

PMID 20923915

Citations 12

Authors

Alex J Mitchell

Timothy G Dinan

Affiliations

Soon will be listed here.

Citing Articles

Multimorbidity in Severe Mental Illness as Part of the Neurodevelopmental Continuum: Physical Health-Related Endophenotypes of Schizophrenia-A Narrative Review.

Genkel V, Domozhirova E, Malinina E Brain Sci. 2024; 14(7).

PMID: 39061465 PMC: 11274495. DOI: 10.3390/brainsci14070725.

Investigation of carotid intima-media thickness in patients with schizophrenia.

Kapici Y, Kapici O, Abus S, Orum M, Ayhan S, Bozkurt M BMC Psychiatry. 2024; 24(1):54.

PMID: 38233818 PMC: 10795201. DOI: 10.1186/s12888-024-05496-7.

Association Between Retinal Features From Multimodal Imaging and Schizophrenia.

Wagner S, Cortina-Borja M, Silverstein S, Zhou Y, Romero-Bascones D, Struyven R JAMA Psychiatry. 2023; 80(5):478-487.

PMID: 36947045 PMC: 10034669. DOI: 10.1001/jamapsychiatry.2023.0171.

Cognitive deficits, clinical variables, and white matter microstructure in schizophrenia: a multisite harmonization study.

Seitz-Holland J, Wojcik J, Cetin-Karayumak S, Lyall A, Pasternak O, Rathi Y Mol Psychiatry. 2022; 27(9):3719-3730.

PMID: 35982257 PMC: 10538303. DOI: 10.1038/s41380-022-01731-3.

Schizophrenia in Translation: Why the Eye?.

Silverstein S, Choi J, Green K, Bowles-Johnson K, Ramchandran R Schizophr Bull. 2022; 48(4):728-737.

PMID: 35640030 PMC: 9212100. DOI: 10.1093/schbul/sbac050.

References

Holt R, Peveler R . Antipsychotic drugs and diabetes--an application of the Austin Bradford Hill criteria. Diabetologia. 2006; 49(7):1467-76. DOI: 10.1007/s00125-006-0279-3. View

Potvin S, Stip E, Sepehry A, Gendron A, Bah R, Kouassi E . Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry. 2007; 63(8):801-8. DOI: 10.1016/j.biopsych.2007.09.024. View

De Hert M, van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A . Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemiol Ment Health. 2006; 2:14. PMC: 1533826. DOI: 10.1186/1745-0179-2-14. View

Zhang Z, Yao Z, Liu W, Fang Q, Reynolds G . Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry. 2004; 184:58-62. DOI: 10.1192/bjp.184.1.58. View

Saari K, Lindeman S, Viilo K, Isohanni M, Jarvelin M, Lauren L . A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort study. J Clin Psychiatry. 2005; 66(5):559-63. DOI: 10.4088/jcp.v66n0503. View

Fernandez-Egea E, Bernardo M, Donner T, Conget I, Parellada E, Justicia A . Metabolic profile of antipsychotic-naive individuals with non-affective psychosis. Br J Psychiatry. 2009; 194(5):434-8. PMC: 2703813. DOI: 10.1192/bjp.bp.108.052605. View

Stober G, Ben-Shachar D, Cardon M, Falkai P, Fonteh A, Gawlik M . Schizophrenia: from the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. World J Biol Psychiatry. 2009; 10(2):127-55. DOI: 10.1080/15622970902898980. View

Tarricone I, Ferrari Gozzi B, Serretti A, Grieco D, Berardi D . Weight gain in antipsychotic-naive patients: a review and meta-analysis. Psychol Med. 2009; 40(2):187-200. DOI: 10.1017/S0033291709990407. View

Meyer J, Nasrallah H, McEvoy J, Goff D, Davis S, Chakos M . The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr Res. 2005; 80(1):9-18. DOI: 10.1016/j.schres.2005.07.015. View

10.

Heila H, Haukka J, Suvisaari J, Lonnqvist J . Mortality among patients with schizophrenia and reduced psychiatric hospital care. Psychol Med. 2005; 35(5):725-32. DOI: 10.1017/s0033291704004118. View

11.

Nikkila H, Muller K, Ahokas A, Miettinen K, Rimon R, Andersson L . Accumulation of macrophages in the CSF of schizophrenic patients during acute psychotic episodes. Am J Psychiatry. 1999; 156(11):1725-9. DOI: 10.1176/ajp.156.11.1725. View

12.

Saddichha S, Manjunatha N, Ameen S, Akhtar S . Metabolic syndrome in first episode schizophrenia - a randomized double-blind controlled, short-term prospective study. Schizophr Res. 2008; 101(1-3):266-72. DOI: 10.1016/j.schres.2008.01.004. View

13.

Bresee L, Majumdar S, Patten S, Johnson J . Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study. Schizophr Res. 2010; 117(1):75-82. DOI: 10.1016/j.schres.2009.12.016. View

14.

Kolotkin R, Corey-Lisle P, Crosby R, Swanson J, Tuomari A, LItalien G . Impact of obesity on health-related quality of life in schizophrenia and bipolar disorder. Obesity (Silver Spring). 2008; 16(4):749-54. DOI: 10.1038/oby.2007.133. View

15.

Ananth J, Venkatesh R, Burgoyne K, Gunatilake S . Atypical antipsychotic drug use and diabetes. Psychother Psychosom. 2002; 71(5):244-54. DOI: 10.1159/000064807. View

16.

Hennekens C, Hennekens A, Hollar D, Casey D . Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005; 150(6):1115-21. DOI: 10.1016/j.ahj.2005.02.007. View

17.

Verma S, Subramaniam M, Liew A, Poon L . Metabolic risk factors in drug-naive patients with first-episode psychosis. J Clin Psychiatry. 2009; 70(7):997-1000. DOI: 10.4088/JCP.08m04508. View

18.

Joukamaa M, Heliovaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V . Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry. 2006; 188:122-7. DOI: 10.1192/bjp.188.2.122. View

19.

Bell R, Farmer S, Ries R, Srebnik D . Metabolic risk factors among medicaid outpatients with schizophrenia receiving second-generation antipsychotics. Psychiatr Serv. 2009; 60(12):1686-9. DOI: 10.1176/ps.2009.60.12.1686. View

20.

Oriot P, Feys J, Mertens de Wilmars S, Misson A, Ayache L, Fagnart O . Insulin sensitivity, adjusted beta-cell function and adiponectinaemia among lean drug-naive schizophrenic patients treated with atypical antipsychotic drugs: a nine-month prospective study. Diabetes Metab. 2008; 34(5):490-6. DOI: 10.1016/j.diabet.2008.03.003. View